Terms: = Colorectal cancer AND PAM50 AND Treatment
4 results:
1. classifieR a flexible interactive cloud-application for functional annotation of cancer transcriptomes.
Quinn GP; Sessler T; Ahmaderaghi B; Lambe S; VanSteenhouse H; Lawler M; Wappett M; Seligmann B; Longley DB; McDade SS
BMC Bioinformatics; 2022 Mar; 23(1):114. PubMed ID: 35361119
[TBL] [Abstract] [Full Text] [Related]
2. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the pam50 risk of recurrence score and intrinsic subtype.
Gnant M; Sestak I; Filipits M; Dowsett M; Balic M; Lopez-Knowles E; Greil R; Dubsky P; Stoeger H; Rudas M; Jakesz R; Ferree S; Cowens JW; Nielsen T; Schaper C; Fesl C; Cuzick J
Ann Oncol; 2015 Aug; 26(8):1685-91. PubMed ID: 25935792
[TBL] [Abstract] [Full Text] [Related]
3. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the pam50 risk of recurrence score.
Sestak I; Cuzick J; Dowsett M; Lopez-Knowles E; Filipits M; Dubsky P; Cowens JW; Ferree S; Schaper C; Fesl C; Gnant M
J Clin Oncol; 2015 Mar; 33(8):916-22. PubMed ID: 25332252
[TBL] [Abstract] [Full Text] [Related]
4. The pam50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Filipits M; Nielsen TO; Rudas M; Greil R; Stöger H; Jakesz R; Bago-Horvath Z; Dietze O; Regitnig P; Gruber-Rossipal C; Müller-Holzner E; Singer CF; Mlineritsch B; Dubsky P; Bauernhofer T; Hubalek M; Knauer M; Trapl H; Fesl C; Schaper C; Ferree S; Liu S; Cowens JW; Gnant M;
Clin Cancer Res; 2014 Mar; 20(5):1298-305. PubMed ID: 24520097
[TBL] [Abstract] [Full Text] [Related]